-$0.79 Earnings Per Share Expected for Achaogen, Inc. (AKAO) This Quarter
Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to report ($0.79) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Achaogen’s earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.99). Achaogen posted earnings of ($1.04) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 24%. The company is scheduled to issue its next quarterly earnings results on Tuesday, March 13th.
On average, analysts expect that Achaogen will report full-year earnings of ($3.06) per share for the current financial year, with EPS estimates ranging from ($3.16) to ($2.92). For the next fiscal year, analysts anticipate that the firm will report earnings of ($3.22) per share, with EPS estimates ranging from ($3.73) to ($2.78). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Achaogen.
Achaogen (NASDAQ:AKAO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.13). Achaogen had a negative net margin of 593.61% and a negative return on equity of 80.44%. The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $2.09 million. During the same period in the previous year, the firm posted ($0.41) earnings per share. The firm’s revenue for the quarter was down 96.4% on a year-over-year basis.
Several equities analysts recently issued reports on AKAO shares. BidaskClub upgraded Achaogen from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 22nd. Mizuho restated a “buy” rating and issued a $28.00 price target on shares of Achaogen in a research report on Monday, October 30th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Achaogen in a research report on Thursday, November 9th. Stifel Nicolaus dropped their price target on Achaogen from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. Finally, Guggenheim assumed coverage on Achaogen in a research report on Tuesday, October 24th. They issued a “buy” rating and a $17.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Achaogen has a consensus rating of “Buy” and a consensus target price of $25.78.
In related news, COO Blake Wise sold 3,576 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $15.99, for a total value of $57,180.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 8.36% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in AKAO. Vanguard Group Inc. grew its holdings in shares of Achaogen by 11.2% in the 1st quarter. Vanguard Group Inc. now owns 1,066,701 shares of the biopharmaceutical company’s stock worth $26,913,000 after acquiring an additional 107,406 shares during the period. Geode Capital Management LLC lifted its stake in Achaogen by 18.6% in the 1st quarter. Geode Capital Management LLC now owns 166,055 shares of the biopharmaceutical company’s stock valued at $4,189,000 after buying an additional 26,100 shares in the last quarter. Morgan Stanley lifted its stake in Achaogen by 117.9% in the 1st quarter. Morgan Stanley now owns 43,698 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 23,644 shares in the last quarter. Bank of America Corp DE lifted its stake in Achaogen by 425.4% in the 1st quarter. Bank of America Corp DE now owns 138,626 shares of the biopharmaceutical company’s stock valued at $3,497,000 after buying an additional 112,239 shares in the last quarter. Finally, Credit Suisse AG purchased a new stake in Achaogen in the 1st quarter valued at approximately $314,000. Institutional investors and hedge funds own 85.81% of the company’s stock.
Shares of Achaogen (AKAO) traded down $0.63 during mid-day trading on Thursday, reaching $11.33. The company had a trading volume of 1,216,772 shares, compared to its average volume of 800,939. Achaogen has a 1 year low of $4.82 and a 1 year high of $27.79. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.99 and a current ratio of 6.99.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/0-79-earnings-per-share-expected-for-achaogen-inc-akao-this-quarter/1741595.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.